Dynamics of Sequencing of Cyclin-Dependent Kinase Inhibitors and Cost Expenditure Analysis in the Management of Metastatic Hormone-Receptor Positive, Human Epidermal Growth Factor 2-Negative Advanced Breast Cancer

Amol Patel; TVSGK Tilak; Vineet G Gupta; Atul Batra; Prashant Mehta; Purvish Parikh; Hemant Malhotra

doi:10.4103/ijmpo.ijmpo_111_19

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(02): 311-313
DOI: 10.4103/ijmpo.ijmpo_111_19

Letter to Editor

Dynamics of Sequencing of Cyclin-Dependent Kinase Inhibitors and Cost Expenditure Analysis in the Management of Metastatic Hormone-Receptor Positive, Human Epidermal Growth Factor 2-Negative Advanced Breast Cancer

Authors

Amol Patel

Malignant Diseases Treatment Center, Army Hospital Research and Referral, New Delhi
TVSGK Tilak

Department of Internal Medicine, Armed Forces Medical College, Pune
Vineet G Gupta

Department of Medical Oncology, Artemis Hospitals, Gurugram
Atul Batra

Department of Medical Oncology, Dr B.R. IRCH, AIIMS, New Delhi
Prashant Mehta

Department of Medical Oncology, Hemato-oncology and BMT, Asian Institute of Medical Sciences, Faridabad, Haryana
Purvish Parikh

Department of Medical Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra
Hemant Malhotra

Sri Ram Cancer Center, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India

Abstract

Full Text

References

References
1 Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375: 1925-36
2 Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J. et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017; 35: 3638-46
3 Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol 2018; 19: 904-15
4 Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375: 1738-48
5 Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018; 379: 1926-36
6 Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): An international, randomised, double-blind, phase 3 trial. Lancet 2016; 388: 2997-3005
7 Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR. et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367: 435-44
8 Palbociclib with an Aromatase Inhibitor for Previously Untreated, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | Guidance and Guidelines | NICE. Available from: https://www.nice.org.uk/guidance/ta495. [Last accessed on 2018 Dec 23]
9 Ribociclib with An Aromatase Inhibitor for Previously Untreated, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | Guidance and Guidelines | NICE. Available from: https://www.nice.org.uk/guidance/ta495. [Last accessed on 2018 Dec 23]
10 Dhakal A, Matthews CM, Levine EG, Salerno KE, Zhang F, Takabe K. et al. Efficacy of palbociclib combinations in hormone receptor-positive metastatic breast cancer patients after prior everolimus treatment. Clin Breast Cancer 2018; 18: e1401-5